Pardes Biosciences, Inc. (PRDS): Price and Financial Metrics
GET POWR RATINGS... FREE!
PRDS Stock Price Chart Interactive Chart >
PRDS Price/Volume Stats
| Current price | $5.78 | 52-week high | $17.76 |
| Prev. close | $5.62 | 52-week low | $4.89 |
| Day low | $5.63 | Volume | 83,900 |
| Day high | $5.82 | Avg. volume | 316,829 |
| 50-day MA | $7.07 | Dividend yield | N/A |
| 200-day MA | $9.84 | Market Cap | 360.55M |
Pardes Biosciences, Inc. (PRDS) Company Bio
Pardes Biosciences, Inc., a pre-clinical stage biotechnology company, engages in developing oral direct acting antivirals. Its antivirals target viral main cysteine protease, an essential viral protein required for coronaviruses to replicate. Pardes Biosciences, Inc. was incorporated in 2020 and is based in Carlsbad, California.
Latest PRDS News From Around the Web
Below are the latest news stories about Pardes Biosciences Inc that investors may wish to consider to help them evaluate PRDS as an investment opportunity.
Pardes Biosciences (PRDS) presents at CROI 2022 - SlideshowThe following slide deck was published by Pardes Biosciences, Inc. in conjunction with this event.... |
Pardes Biosciences Presents Interim Clinical Data from Ongoing PBI-0451 Phase 1 Trial Supporting the Potential of PBI-0451 as a Stand-Alone Oral Regimen for COVID-19 at Conference on Retroviruses and Opportunistic Infections 2022PBI-0451 administered twice-daily as a stand-alone agent achieves and maintains PK exposures anticipated to provide potent antiviral activity against SARS-CoV-2 PBI-0451 has been generally well-tolerated and has shown good oral bioavailability Company to host conference call and webcast Tuesday, February 15, 2022 at 3:00 p.m. PT / 6:00 p.m. ET CARLSBAD, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-045 |
Pardes Biosciences to Host Virtual Investor EventCompany to host conference call and webcast at 3 p.m. PT on Tuesday, February 15, 2022CARLSBAD, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e. COVID-19), today announced that a virtual investor event will be hosted by the company’s management team |
Pardes Biosciences to Present Clinical Data from Ongoing PBI-0451 Phase 1 Trial at Conference On Retroviruses And Opportunistic Infections 2022CARLSBAD, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e. COVID-19), today announced that a late-breaker poster presentation sharing clinical data from the ongoing PBI-0451 Phase 1 trial will be presented at the 29th Conference On Retroviruses And |
Monashee Investment Management LLC Buys Vanguard Total Stock Market ETF, Hyperfine Inc, Agree ...Investment company Monashee Investment Management LLC (Current Portfolio) buys Vanguard Total Stock Market ETF, Hyperfine Inc, Agree Realty Corp, Pardes Biosciences Inc, DocGo Inc, sells Maravai LifeSciences Holdings Inc, SomaLogic Inc, MoneyLion Inc, RBC Bearings Inc, BioAtla Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Monashee Investment Management LLC. |
PRDS Price Returns
| 1-mo | -22.21% |
| 3-mo | -13.73% |
| 6-mo | -60.79% |
| 1-year | -42.14% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -64.69% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...